NOTE: This video is ONLY available to watch in selected countries and geographies [geoip-content country=”AF, AL, DZ, AD, AO, AM, AT, AZ, BH, BY, BE, BJ, BA, BW, BG, BF, BI, CM, CV, CF, TD, KM, CG, CD, CI, HR, CY, CZ, DK, DJ, EG, GQ, ER, EE, ET, FO, FI, FR, GA, GM, GE, DE, GH, GI, GR, GG, GN, GW, IQ, IR, IE, IM, IL, IT, JE, JO, KZ, KE, KW, KG, LV, LB, LS, LR, LY, LI, LT, LU, MK, MG, MW, ML, MT, MR, MU, MD, MC, ME, MA, MZ, NA, NL, NE, NG, NO, OM, PS, PL, PT, QA, RE, RO, RU, RW, SM, ST, SA, SN, RS, SC, SL, SK, SI, SO, ZA, ES, SD, SE, CH, SY, TJ, TZ, TG, TN, TR, TM, UG, UA, AE, GB, VA, YE, ZM, ZW”]
The SUCCESS PTA Study examining a real-world population of peripheral arterial disease (PAD) patients has produced “very convincing” data on the benefits of the SELUTION SLR™ Drug-Eluting Balloon (Cordis), according to principal investigator Michael Lichtenberg (Arnsberg, Germany).
Sitting down in the CX Studio at this year’s Charing Cross Symposium (23–25 April, London, UK), Lichtenberg highlights the fact that—across an array of complex case types and anatomies—the study found a rate of freedom from clinically driven target lesion revascularisation (CD-TLR) close to 90%, and ultimately demonstrated sirolimus to be a safe and efficient PAD treatment option.
This video is sponsored by Cordis. [/geoip-content]
